Item 8.01 Other Events.

On October 2, 2020, bluebird bio, Inc. ("bluebird"or the "Company") issued a press release announcing that the European Medicines Agency (EMA) accepted the Company's marketing authorization application (MAA) for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy for the treatment of patients with cerebral adrenoleukodystrophy (CALD).

The full text of bluebird's press release is being furnished as Exhibit 99.1 to this Current Report on Form 8­K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
    Exhibit
      No.                                             Description
     99.1               Press release issued by bluebird bio, Inc. on October 2, 2020.
      104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses